Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 30, 2016 07:01 ET | Source: Agios Pharmaceuticals, Inc.

Agios Announces Initiation of Phase 1/2 Frontline Combination Study of AG-221 or AG-120 with VIDAZA® (azacitidine for injection) in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients Not Eligible for Intensive Chemotherapy

CAMBRIDGE, Mass., March 30, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced...
March 01, 2016 07:01 ET | Source: Agios Pharmaceuticals, Inc.

Agios to Present at the Cowen and Company 36th Annual Health Care Conference on Tuesday, March 8

CAMBRIDGE, Mass., March 01, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced...
February 18, 2016 07:01 ET | Source: Agios Pharmaceuticals, Inc.

Agios Reports Fourth Quarter and Full Year 2015 Financial Results and Highlights Key 2016 Milestones

- First Data from Phase 2 DRIVE PK Study for AG-348 in PK Deficiency and Phase 1 Healthy Volunteer Study for AG-519 to be Submitted for Presentation at EHA - - Late-stage AG-221 and AG-120 IDH...
February 11, 2016 07:30 ET | Source: Agios Pharmaceuticals, Inc.

Agios to Webcast Conference Call of Fourth Quarter and Full Year 2015 Financial Results on February 18, 2016

CAMBRIDGE, Mass., Feb. 11, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced...
February 08, 2016 07:30 ET | Source: Agios Pharmaceuticals, Inc.

Agios Appoints Steve Hoerter as Chief Commercial Officer

CAMBRIDGE, Mass., Feb. 08, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the...
February 03, 2016 16:01 ET | Source: Agios Pharmaceuticals, Inc.

Agios to Present at the Leerink Partners 5th Annual Global Healthcare Conference on Wednesday, February 10

CAMBRIDGE, Mass., Feb. 03, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the...
January 11, 2016 07:30 ET | Source: Agios Pharmaceuticals, Inc.

Agios Outlines Key 2016 Goals and Priorities

- Complete Enrollment of 125-Patient Expansion Cohorts for AG-221 and AG-120 in Relapsed/Refractory Acute Myeloid Leukemia in Second Half of 2016...
January 04, 2016 08:16 ET | Source: Agios Pharmaceuticals, Inc.

Agios to Present at the 34th Annual J.P. Morgan Healthcare Conference on Monday, January 11

CAMBRIDGE, Mass., Jan. 04, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the...
December 18, 2015 07:30 ET | Source: Agios Pharmaceuticals, Inc.

Agios Announces Initiation of Phase 1b Frontline Trial of AG-221 or AG-120 in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients

CAMBRIDGE, Mass., Dec. 18, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the...
December 06, 2015 16:31 ET | Source: Agios Pharmaceuticals, Inc.

Agios Announces Data from Ongoing Phase 1/2 Trial of AG-221 Showing Durable Responses in Patients with Advanced Hematologic Malignancies

- Patients on Study for up to 18 Months with a Median Response Duration of 6.9 Months in Relapsed/Refractory Acute Myeloid Leukemia (AML) - - Enrollment Complete for Four 25-Patient Expansion...